Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
September 29, 2026 7:16 AM
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented, "Summit and AstraZeneca ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
